The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Vanda Pharmaceuticals Inc

Nasdaq: VNDA
Last

(U.S.) $9.26

Today's change-0.04 -0.43%
Updated April 1 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Vanda Pharmaceuticals Inc

Nasdaq: VNDA
Last

(U.S.) $9.26

Today's change-0.04 -0.43%
Updated April 1 4:00 PM -4GMT. Delayed by at least 15 minutes.

Vanda Pharmaceuticals Inc down (U.S.)$0.04

Vanda Pharmaceuticals Inc closed lower Wednesday, dropping (U.S.)$0.04 or 0.43% to (U.S.)$9.26. Over the last five days, shares have gained 3.00%, but are down 35.34% for the last year to date. Shares have underperformed the S&P 500 by 54.38% during the last year.

Key company metrics

  • Open(U.S.) $9.27
  • Previous close(U.S.) $9.30
  • High(U.S.) $9.45
  • Low(U.S.) $9.06
  • Bid / Ask-- / --
  • YTD % change-35.34%
  • Volume476,616
  • Average volume (10-day)1,180,922
  • Average volume (1-month)966,292
  • Average volume (3-month)846,325
  • 52-week range(U.S.) $8.34 to (U.S.) $17.69
  • Beta1.91
  • Trailing P/E30.33×
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.31
Updated April 1 4:00 PM -4GMT. Delayed by at least 15 minutes.
S&P TSX0.27%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014
Revenue1515119
Total other revenue--------
Total revenue1515119
Gross profit151411--
Total cost of revenue110--
Total operating expense-54163236
Selling / general / administrative18122928
Research & development4337
Depreciation / amortization1111
Interest expense (income), net operating--------
Unusual expense (income)-78------
Other operating expenses, total--------
Operating income70-1-22-27
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax70-1-22-27
Income after tax70-1-22-27
Income tax, total0000
Net income70-1-22-27
Total adjustments to net income--------
Net income before extra. items70-1-22-27
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items70-1-22-27
Inc. avail. to common incl. extra. items70-1-22-27
Diluted net income70-1-22-27
Dilution adjustment0--00
Diluted weighted average shares39343434
Diluted EPS excluding extraordinary itemsvalue per share1.77-0.04-0.64-0.79
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share-0.20-0.04-0.64-0.79